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The systemic fluoroquinolones (FQs) have been used for >30 years for 
a variety of infectious conditions, and have been among the most wide­
ly prescribed antibiotics globally. In the USA, 32.5 million prescrip tions 
for oral FQs were issued in 2015, representing 101 prescrip tions/
1 000 population, and of these, ciprofloxacin comprised 20.3 million 
or 63 prescriptions/1 000 population.[1] In the hospital setting, ~3.8 million 
patients billed for an injectable FQ in 2011.[2] 
During this time, these drugs were lifesaving in many instances, 
but were also associated with significant adverse effects, including 
peripheral neuropathy, photosensitivity, prolonged QT interval, 
hypoglycaemia and tendon rupture. The Food and Drug Admin­
istration (FDA) in the USA and the European Medicines Agency 
(EMA) have highlighted these and other adverse effects and have 
suggested that, where possible, alternative agents should be 
used.[3,4]
New adverse events and warnings 
More recently, these warnings have been extended to include a 
potential risk for aortic dissection, with an increased risk from a 
baseline of 9/100 000 to 300/100 000, and a recommendation that 
the FQs should be avoided in patients at risk of an aortic aneurysm, 
including the elderly and those with peripheral vascular disease, 
uncontrolled hypertension, vasculitic syndromes and diseases such 
as Marfan’s and Ehlers­Danlos syndromes.[5]
The EMA has also extended a warning of potential tendon rupture 
to include tendinitis, myalgia, muscle weakness, arthralgia and joint 
swelling, and also warned of a syndrome that includes peripheral 
neuropathy, psychosis, anxiety, insomnia, depression, hallucinations, 
suicidal thoughts, confusion and impairment of vision, hearing, smell 
and taste.[6,7] Older patients, those with renal dysfunction, transplant 
recipients and those receiving concomitant corticosteroids are at 
higher risk of side­effects. According to the FDA and EMA, FQs 
‘can be associated with prolonged (up to months or years) serious, 
disabling and potentially irreversible drug reactions affecting several, 
sometimes multiple, systems, organ classes and senses’.[6] The overall 
condition has been termed ‘fluoroquinolone­associated disability 
syndrome’ (FADS).[7] The existence of the entire constellation of 
FADS relies on patient testimony and does not as yet have a 
recognised pathogenetic mechanism. Therefore, the actual incidence 
of FADS is not known. With regard to tendon rupture, tendinitis and 
aortic aneurysm, FQs display a high affinity for connective tissue, 
particularly in cartilage and bone. In an evaluation of the incidence in 
>11 000 patients, rates for tendinitis of 2.4 /10  000 prescriptions, and 
for tendon rupture of 1.2/10  000 prescriptions, have been reported.[8]
Mechanisms of harm
There are many proposed mechanisms for these adverse events, 
which include ischaemia, degradation of the tendon matrix 
and an alteration of tenocyte activity.[9] FQs, and in particular 
ciprofloxacin, also enhance matrix metalloproteinase expression 
in tendon tissue and reduce collagen synthesis by inhibition of 
tenocyte proliferation.[10,11] A very recent and important publication 
has shown that ciprofloxacin inhibits mitochondrial topoisomerase 
2­beta, which regulates supercoiling of mitochondrial DNA. This 
results in accumulation of positively supercoiled DNA, which causes 
transcription and replication initiation failure with depletion of 
mitochondrial DNA copy number.[12] This effect might be caused by 
oxidative damage, which FQs induce in various cell types.[13,14] This 
blocks cellular proliferation and differentiation and may provide a 
reason for the prolonged effects seen in some patients. 
Whatever the aetiology and incidence of these conditions, EMA 
and FDA reports have led to considerable confusion among the 
general public and healthcare practitioners as to when it would be 
appropriate to use these agents. 
Is there any place for the 
fluoroquinolones?
Whereas it is relatively easy to decide which patients should not 
receive FQs, does this mean that we should abandon these agents as a 
class? The FQs should not be used to treat mild or moderate bacterial 
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infections unless other antibacterial agents commonly recommended 
for these infections cannot be used. Conditions that should not be 
treated with a FQ (or any antibiotic) include viral infections, the 
common cold, influenza, acute bronchitis and pharyngotonsillitis 
(unless <16 years of age and streptococcus is suspected, and even 
in that case one can wait until results of a rapid test for group A 
streptococcus are available, and if antibiotics are indicated, a number 
of other more narrow­spectrum antibiotics are as effective).[15]
Travellers’ diarrhoea
Similarly, diarrhoea not associated with fever, bloody stools 
or other signs of systemic sepsis (i.e. those caused by shigella, 
campylobacter, Clostridium difficile, and protozoal infections) does 
not benefit from any antibiotic, including metronidazole, even in the 
immunocompromised host. Antibiotics – FQs in particular – should 
be avoided in this setting, as they are ineffective and predispose 
to colonisation of the gut by resistant organisms.[16] Most cases of 
travellers’ diarrhoea are caused by enterotoxigenic Escherichia coli 
(ETEC), occur in the first week of travel, are usually mild (<6 stools/
day) and do not disrupt normal activities. Most cases last 3 ­ 5 days 
and resolve without treatment. When the diarrhoea is associated 
with additional symptoms, as indicated above, and with interruption 
of normal activities, it is classed as moderate to severe and may 
need to be treated with an antibiotic. FQs have been the traditional 
agents used in this setting; however, several systematic reviews 
that compared antibiotics, e.g. FQs, azithromycin, and rifaximin v. 
placebo, showed consistent shortening of duration of diarrhoea from 
3 days to 1.5 days with the use of all these antibiotics. If an antibiotic 
is used, it is best to avoid a FQ and preferably use azithromycin for 
only 1 ­ 3 days.[17,18]
Salmonella infections (typhi and paratyphi)
Whereas empiric treatment is based on regional susceptibility,  FQs 
are considered by many experts to be the drug of choice for 
susceptible isolates; it is still reasonable to use these agents in this 
setting.[19,20] However, with regard to empiric therapy, 1 in 7 isolates 
of Salmonella typhi in SA is resistant to FQs, whereas 100% are 
susceptible to azithromycin, which may be an appropriate initial 
choice.[21] Thereafter, antibiogram­directed therapy is vital. Other 
alternatives include third­generation cephalosporins; however, 
extended­spectrum beta­lactamase production, which renders these 
organisms resistant to ceftriaxone, is an increasing problem in both 
typhoid and paratyphoid infections. If the organism is sensitive to 
both ceftriaxone and FQs, patients improve more rapidly with the 
latter; however, the combination of ceftriaxone and azithromycin 
leads to more rapid resolution than ceftriaxone alone and may be an 
effective option.[22] Treatment is for 2 weeks with either agent. 
Lower respiratory tract infections
With regard to community­acquired pneumonia, FQs, particularly 
moxifloxacin or levofloxacin, have been recommended as alternatives 
to beta­lactams (BLs), especially in the case of severe allergy. It is 
recommended that they should only be used as a last resort, where 
no other agent is available.[23] 
With regard to acute exacerbations of chronic obstructive pulmonary 
disease, only patients with a C­reactive protein of >40 mg/L, those who 
have all three of the following symptoms, i.e. increased sputum 
volume, purulence and dyspnoea, or two of these features, where one 
is increased sputum purulence, should receive an antibiotic. When 
an antibiotic is deemed necessary, appropriate therapy should usually 
consist of a BL, inclusive of amoxicillin, cefuroxime or cefpodoxime, 
a combination of a BL and a BL inhibitor or a macrolide, where 
pneumococcal resistance to macrolides is low. For hospitalised 
patients with the risk of pseudomonas or other more­resistant 
organisms, antipseudomonal agents, such as piperacillin­tazobactam 
or cefepime, may be considered. It is recommended that these 
patients have a sputum culture performed, and that the antibiotic 
choice be based, where possible, on the results.[24]
With regard to bronchiectasis, where the patient is not considered 
ill enough to require hospital admission, and the cultured organism 
is a pseudomonas or one of the Enterobacteriaceae sensitive to 
ciprofloxacin but resistant to other oral antibiotics, the FQs could be 
considered. 
Urinary tract infections and prostatitis
With regard to urinary tract infections, it is reasonable to use an 
oral FQ where resistance dictates that the alternative would be to 
admit the patient to hospital to use a parenteral agent, such as a 
carbapenem. It is important, however, that microscopy and culture of 
urine be performed to optimise therapy and that the prescription be 
based on sensitivities. 
Acute bacterial prostatitis, as opposed to chronic prostatitis (which 
is usually not bacterial in origin), is due to E. coli in 58 ­ 88% of 
cases, Proteus species in 3 ­ 6%, other enterobacterales, i.e. Klebsiella, 
Enterobacter and Serratia species in 3 ­ 11%, Pseudomonas aeruginosa 
in 3 ­ 7% and occasionally Staphylococcus aureus and streptococcal or 
enterococcal infection.[25­27] Although there are no comparative trials 
evaluating optimal antimicrobial therapy, FQs are a reasonable choice, 
provided that the organism is sensitive and that the alternative would 
be the need to admit the patient to hospital for parenteral therapy. 
Ciprofloxacin attains a ~2­fold higher concentration in the prostate 
than in the plasma, and levofloxacin a ~3­fold higher concentration. 
More recently, high­dose oral fosfomycin has been recommended as 
an effective outpatient therapy. An oral regimen of 3 g daily for 1 week, 
followed by 3 g every second day for a total treatment duration of 
6 ­ 12 weeks or 3 g every second or third day for 6 weeks, appears to 
be effective.[28­30] This has recently been confirmed to be extremely 
effective in a prospective observational study of 44 patients, where the 
majority of organisms were FQ resistant. Cure was achieved in 82% 
at end of treatment (EOT) and in 80% and 73% at 3 and 6 months, 
respectively. Microbiological eradication was achieved in 86% and 
77% at EOT and 6 months, respectively.[31] The longer course was 
reserved for patients with prostatic calcification.
Other agents that penetrate prostatic fluid and would be effective 
if the organism is sensitive are the macrolides, trimethoprim­
sulfamethoxazole (TMP/SMX) and doxycycline.[27,32] If the organism is 
resistant to these agents, admission is required for intravenous therapy 
with antibiotics, such as ertapenem, tigecycline or ceftriaxone, the 
latter particularly in the case of Neisseria gonorrhoeae. Community­
acquired enterococcal infections can be treated with amoxicillin, and 
staphylococcal infections with oral cloxacillin or intravenous (IV) 
cefazolin (1 g IV every 8 hours). If there are risk factors, or a history 
of methicillin­resistant S. aureus, vancomycin or linezolid may be 
administered. 
Prosthetic joint infections and osteomyelitis
The FQs are useful in the management of prosthetic joint infection 
(PJIs) if the offending organism is susceptible. Management is 
primarily surgical and a 2­stage arthroplasty is most commonly 
employed. Antibiotic therapy is most frequently administered for 6 weeks, 
initially for 2 weeks with parenteral therapy and thereafter for 4 weeks 
with oral therapy.[33] Oral ciprofloxacin is often effective against many 
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Gram­negative pathogens and has also been used successfully with 
rifampicin for staphylococcal infections in an IV to oral switch if the 
organism is susceptible.[34] However, other oral anti­staphylococcal 
agents that might be effective are TMP/SMX and clindamycin. Oral 
linezolid has limited use, given the toxicity that occurs after 14 days 
of therapy.
A very recent study showed that oral therapies, including the 
FQs, were effective in treating osteomyelitis.[35] Depending on 
susceptibility, a FQ would be acceptable if it decreased the duration 
of IV therapy and allowed earlier discharge of patients. Patients 
would have to be observed closely for adverse events, given the long 
duration of use.
Intensive care unit-acquired infections
Intensive care unit (ICU) use of the FQs has been limited because 
of the potential for this class of drugs to cause collateral damage, 
i.e. enhance the emergence of resistance in organisms for which the 
antibiotic was not originally intended.[36] However, FQs are used as 
carbapenem­sparing agents for extended­spectrum beta­lactamase 
producers if they are sensitive, and along with TMP/SMX are also 
valuable for the treatment of organisms such as Stenotrophomonas 
maltophilia and Burkholderia cepacia.[37,38] 
Meningococcal prophylaxis 
Meningococcal infections are potentially fatal and easily transmissible. 
Prophylaxis is warranted for close contacts and for exposed healthcare 
workers. A single dose of ciprofloxacin 500 mg was the recommended 
protocol; however, as it is not known if duration of therapy is 
necessarily the determinant of toxicity, and because ciprofloxacin 
resistance has been reported, it may be wise to use an alternative 
regimen. This consists of rifampicin 600 mg twice daily for 2 days or 
a single dose of ceftriaxone IV.[39­41] This regimen might not always 
be practical if all the children in a classroom need prophylaxis. 
Paediatric doses differ from those for adults.
Mycobacterial infections
Another indication for FQ use is the management of Mycobacterium 
avium intracellulare infections; however, FQs have generally been 
relegated to second­line therapy, as outcomes are inferior to macrolide­
based regimens, specifically clarithromycin or azithromycin, along 
with ethambutol, and rifamycins (rifampicin, rifabutin), with or with­ 
out aminoglycosides in more severe infections.[42,43]
The new World Health Organization guidelines for the 
management of multidrug­resistant Mycobacterium tuberculosis 
include levofloxacin/moxifloxacin, linezolid and bedaquiline in their 
category A agents, i.e. those that should be used first.[44] Thereafter, 
the recommendation is to use agents in categories B or C if those 
in the preceding category cannot be used. It is unlikely that this 
recommendation would be withdrawn, given the potential toxicities 
of the other agents and the high mortality of patients with the disease. 
Fluoroquinolone use in situations of beta-lactam allergy
When considering an alternative agent to BL, it should be recognised 
that BL allergy is exceedingly rare and, where an allergy to penicillin 
exists, there is little cross­reactivity between the second­ and third­
generation cephalosporins. Unless the patient has developed a severe 
reaction inclusive of urticaria or anaphylaxis (type 1 reaction), 
or severe non­IgE­mediated reactions, such as Stevens­Johnson 
syndrome/toxic epidermal necrolysis, drug­induced hypersensitivity 
syndrome, drug reaction with eosinophilia and systemic symptoms 
(DRESS syndrome), renal failure, cytopenias, serum sickness or 
any other life­threatening reaction, the first­ and second­generation 
cephalosporins can be considered safe.[45] It is, however, probably 
necessary to perform allergy testing more frequently than is currently 
done, as most patients who believe they are allergic to BL are probably 
not.[46] 
Conclusions
The overall aim is to reduce the use of FQs, probably also as topical 
agents, as there is emerging evidence that they may also be harmful 
when used in this manner.[47] However, as mentioned above, there is a 
role for these agents in certain circumstances, both in the community 
and in hospital. It is nevertheless important to be aware that prescrip­
tion of FQs may have significant unwanted consequences and it is 
therefore important to consider carefully the circumstances where 
use would be rational.
A summary of recommendations is given in Box 1.
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